Triveni Bio
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
99 Coolidge Ave, Watertown, Massachusett...Website
triveni.bioRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
2
1
1
About Triveni Bio
Triveni Bio is a biotechnology company at the forefront of novel antibody-based therapies for immunological and inflammatory disorders. Using a genetics-informed, precision medicine approach, the company seeks to establish proof-of-concept early in the drug development process by leveraging deep insights into genetic and mechanistic biology.Explore more
Triveni Bio Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Triveni Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Triveni Bio recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Triveni Bio
Triveni Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Triveni Bio has recently received funding, and reach out quickly before it becomes old news!
Check out if Triveni Bio is spiking on competitors!
Product Launch: Get notified when Triveni Bio launches new products
Website visits: Recent activity has been detected on your website
Click to see if Triveni Bio had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Triveni Bio has new funding data
Recommended Actions
Reach out to Masked Content who joined Triveni Bio as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
Triveni Bio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Triveni Bio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Triveni Bio.
Triveni Bio financials insights
Gather financial insights about Triveni Bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Series A
$92M
2024
Series B
$115M
2026
Series C
$65M
Triveni Bio Tech Stack
A closer look at the technologies used by Triveni Bio
Most Recent Scoops
Hiring Plans
Triveni Bio has more open roles in Operations than it has had at any time in the past 6 months.
Hiring Plans
Open Position
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
Open Position
Triveni Bio News & Media
Triveni Bio Doses First Healthy Volunteers with Next-Generation Bispecific Antibody TRIV-573 Targeting Kallikreins 5 & 7 and Interleukin 13 in Phase 1 Clinical Trial
— Dual mechanism uniquely combines barrier repair (KLK5/7) and established anti-inflammatory blockade (IL-13) to bring a first-in-class therapeutic to patients in atopic dermatitis — — Phase 2 patient proof-of-concept study in moderate-to-severe atopic dermatitis expected to initiate...Triveni Doses First Subject in Global Phase 2 Proof of Concept Study of TRIV-509 in Atopic Dermatitis, Presents Translational Data at 2025 EADV Congress Demonstrating Novel Biology in Patient Samples
-- Phase 2 atopic dermatitis (AD) study advances TRIV-509, a differentiated anti-KLK5/7 antibody with the potential to deliver a new level of clinical efficacy and a convenient quarterly subcutaneous dosing option -- -- Oral presentation at EADV Congress 2025 bridges preclinical and...Triveni Bio Doses First Healthy Volunteers in Clinical Trial for TRIV-509, Coinciding with Preclinical Data Presentations Further Validating Novel Kallikrein 5/7 Biology in Atopic Dermatitis
-- Triveni Bio enters the clinic with TRIV-509 and plans to initiate two additional patient studies in the second half of 2025 -- -- Scientific presentations elucidate the importance of KLK5/7 in AD disease pathology and support advancement of second-generation bispecific antibody,...Triveni Bio: $115 Million (Series B) Closed To Advance Novel Antibody Treatments For I&I Disorders
Triveni Bio, a biotech company advancing novel antibody treatments for I&I disorders, announced a $115 million Series B to support pipeline expansion. The funding round was led by Goldman Sachs Alternatives with significant participation from additional new investors Fidelity Management & Research Company and Deep Track Capital, and Series A investors Atlas Venture, Cormorant Asset Management, OrbiMed, Viking Global Investors, and Invus.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Triveni Bio
Sign Up For FreeTo access detailed company insights
Triveni Bio is a biotechnology company at the forefront of novel antibody-based therapies for immunological and inflammatory disorders. Using a genetics-informed, precision medicine approach, the company seeks to establish proof-of-concept early in the drug development process by leveraging deep insights into genetic and mechanistic biology.... Read More
